WCM Investment Management LLC Has $1.15 Million Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

WCM Investment Management LLC increased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 3.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 17,540 shares of the biotechnology company’s stock after acquiring an additional 595 shares during the quarter. WCM Investment Management LLC’s holdings in BioMarin Pharmaceutical were worth $1,148,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. nVerses Capital LLC bought a new stake in shares of BioMarin Pharmaceutical in the 3rd quarter valued at about $28,000. TD Private Client Wealth LLC lifted its stake in shares of BioMarin Pharmaceutical by 57.4% in the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 186 shares during the period. Meeder Asset Management Inc. boosted its holdings in BioMarin Pharmaceutical by 920.8% in the third quarter. Meeder Asset Management Inc. now owns 735 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 663 shares during the last quarter. GAMMA Investing LLC increased its position in BioMarin Pharmaceutical by 56.1% during the 3rd quarter. GAMMA Investing LLC now owns 782 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 281 shares during the period. Finally, True Wealth Design LLC increased its position in BioMarin Pharmaceutical by 13,400.0% during the 3rd quarter. True Wealth Design LLC now owns 810 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 804 shares during the period. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Trading Down 0.7 %

NASDAQ:BMRN opened at $63.50 on Tuesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. BioMarin Pharmaceutical Inc. has a one year low of $60.63 and a one year high of $94.85. The company has a market cap of $12.10 billion, a PE ratio of 38.02, a PEG ratio of 0.57 and a beta of 0.28. The firm has a 50-day moving average of $64.97 and a 200-day moving average of $72.08.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on BMRN shares. Royal Bank of Canada restated a “sector perform” rating and issued a $80.00 price target on shares of BioMarin Pharmaceutical in a research report on Wednesday, October 30th. Wolfe Research initiated coverage on shares of BioMarin Pharmaceutical in a report on Friday, November 15th. They issued an “outperform” rating and a $95.00 target price on the stock. UBS Group increased their price target on BioMarin Pharmaceutical from $104.00 to $106.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Citigroup dropped their price objective on BioMarin Pharmaceutical from $93.00 to $81.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 30th. Finally, Evercore ISI decreased their target price on BioMarin Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Wednesday, October 30th. Seven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $94.20.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.